The Latest Convergence of AI & HPC, the 29th HPC Connection Workshop at ISC22
23.5.2022 10:09:00 EEST | Business Wire | Press release
The 29th HPC Connection Workshop (HPCC) will be held online at 2pm (CEST) on May 30, 2022, at ISC22 with the theme "The Latest Convergence of AI & HPC." World renowned experts and industry leaders will introduce the latest in the convergence of AI and HPC.
Featured speakers include:
- Jean-Marc Denis, Chief Strategy Officer of SiPearl, will describe new paradigms and challenges in Exascale era with the perspective of the key decisions made for Rhea processor architecture and design. Rhea is built on Arm's Neoverse V1 processor architecture, but it also has 29 RISC-V cores deployed as controllers. Rhea is planned to be deployed in an European Exascale supercomputer in 2023.
- Radoslav Danilak, CEO of Tachyum, will provide an overview of the features and benefits of Tachyum Prodigy, the world’s first Universal Processor. With 128 64-bit CPU cores operating at up to 5.7GHz, Prodigy not only handles general-purpose computing, HPC, and AI workloads on a single chip, it does so with a power budget that's 10 times lower than that of traditional hardware and at one-third the cost.
- Wolfgang Gentzsch, President of UberCloud, will summarize UberCloud’s 10 year achievements and present several customer use cases, and elaborate on UberCloud’s fully automated, portable, self-service, and multi-cloud engineering platform.
- Shu Yin, Assistant Professor at ShanghaiTech University, will share how to optimize HPC applications from the perspective of I/O, and will demonstrate best practices and use cases.
- Weizheng Lu, Tech Lead of Public Computing Center at Renmin University of China, will talk about Jax-Quant-Finance, and the High Performance Quantitative Library which brings HPC, Deep Learning, and Financial Mathematics together to accelerate financial problems time-to-resolution on heterogeneous platforms.
- Longxiang Li, Senior HPC engineer at Inspur Information, will detail the building of data-driven scientific workflows by coupling HPC with machine learning methods and introduce Inspur’s recent achievements in the fields of materials science, CFD, and ocean modeling.
|
The 29th HPC Connection Workshop Digital 2pm (CEST) May 30, 2022 Online |
|
Agenda |
|
Rhea Processor: Overall Strategic Directions and Specifications Jean-Marc Denis Chief Strategy Officer (CSO), SiPearl |
|
Tachyum Prodigy, The World’s First Universal Processor Radoslav Danilak CEO, Tachyum |
|
10 Year HPC in the Cloud: From Early Cloud Experiments to a Fully Automated Simulation Multi-Cloud Platform for Complex Engineering Workflows Wolfgang Gentzsch President of UberCloud |
|
Optimize HPC applications from the I/O perspectives Shu Yin Assistant Professor, ShanghaiTech University |
|
Jax-Quant-Finance: Bring HPC, Deep Learning and Financials Mathematics together Weizheng Lu Tech Lead of Public Computing Center, Renmin University of China |
|
Building data-driven scientific workflows with machine learning and HPC applications Longxiang Li Senior HPC engineer, Inspur Information |
Click here to register: http://www.asc-events.net/HPCC/ISC22.php
About HPC Connection Workshop
The HPC Connection Workshop is an international High Performance Computing event organized by the Asia Supercomputer Community and Inspur Information. This event takes place three times a year: during ASC in China, ISC in Germany, and SC in the USA. Top researchers and leading professionals from around the world gather at the workshops to discuss the latest developments and disruptive technologies in AI and supercomputing. Visit ASC's website for highlights and videos of the past events: (http://www.asc-events.org/).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005035/en/
Contact information
Fiona Liu
media@asc-events.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
